ACE2 and COVID-19: Intestinal ACE2/B0AT1 cell surface expression is downregulated as a result of SARS-CoV-2 infection in ACE2-expressing intestinal epithelial cells, which consequently increases plasma bacterial LPS and worsens systemic inflammation in COVID-19 patients [13].